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Abstract: Background: Individuals with an "At Risk Mental State" (or "prodromal" symptoms) have a 20-40% 
chance of developing psychosis; however it is difficult to predict which of them will become ill on the basis of 
their clinical symptoms alone. We examined whether neurophysiological markers could help to identify those 
who are particularly vulnerable.
Method: 35 cases meeting PACE criteria for the At Risk Mental State (ARMS) and 57 controls performed an 
auditory oddball task whilst their electroencephalogram was recorded. The latency and amplitude of the 
P300 and N100 waves were compared between groups using linear regression.
Results: The P300 amplitude was significantly reduced in the ARMS group [8.6 ±6.4 microvolt] compared to 
controls [12.7 ±5.8 microvolt] (p<0.01). There were no group differences in P300 latency or in the amplitude 
and latency of the N100. Of the at-risk subjects that were followed up, seven (21%) developed psychosis. 
Conclusion: Reduction in the amplitude of the P300 is associated with an increased vulnerability to 
psychosis. Neurophysiological and other biological markers may be of use to predict clinical outcomes in 
populations at high risk.
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Please find attached a fully revised manuscript titled “Abnormal P300 in people with high 
risk of developing psychosis”. We also enclose a letter with the comments from the 
reviewers and our detailed answers on how we have done all the changes requested.
My coauthors and I would be grateful if you could consider this new version for 
publishing in Neuroimage.
Your Sincerely
Elvira Bramon MD, PhD
Corresponding author
1. Second letter to editor
1RESPONSE TO REVIEWS - Ms. No.: NIMG-07-745
Title: Abnormal P300 in people with high risk of developing psychosis Corresponding Author: dr 
Elvira Bramon
Authors: Madiha Shaikh, BSc  Psychology; Matthew  Broome, BSc, MBChB, MRCPsych; Julia 
Lappin, MBBS, MRCPsych; Daniel Berge, MD; Fern  Day, BSc; James Woolley, BSc, MBBS, 
MRCP, MRCPsych; Paul Tabraham, BSc, DClinPsy; Merce Madre, MD; Louise Johns, MA, DPhil,  
DClinPsy; Lucia Valmaggia, MSc, PhD; Victor Perez, MD, PhD; Pak Sham, MBBS, MRCPsych, 
PhD; Robin  Murray, MD, DSc; Philip McGuire, MBBS, MRCPsych, MD, PhD
RESPONSE TO REVIEWER #1: 
Thank you for your comments, which have improved the paper and are very encouraging for us. 
Below are your suggestions in blue italic and how we have amended the manuscript accordingly in 
black.
This study investigated the differences in P300 between at-risk individuals for psychosis and a 
matched control group. Reduced P300 amplitude was found associated with at risk state, 
independent of other demographic variables. The manuscript is well written, is based on standard 
ERP techniques and the results are clearly presented.
As a minor suggestion, I would request the authors include the criteria of Yung et al. as the journal 
is not widely available.
These criteria have now been briefly mentioned in the paper. See 1st paragraph of methods 
section page 4.
Please state if those individuals who progressed to psychosis during follow-up did differ from the 
others in demographic and ERP variables. Even though preliminary at this stage, this would be of 
considerable interest!
Compared to the rest of cases at risk, the seven individuals who went on to develop psychosis did 
not differ significantly in sex or ethnicity (Pearson chi-square p= 0.49 and p=0.76 respectively) or 
age (t-test; p=0.93). Those making a transition to psychosis were marginally more educated but 
this was only at trend level with a 3 year average difference in the age at which they completed 
their studies (t-test; p=0.07). 
Similarly, logistic regression analyses showed that compared to those who remained at risk, the 
seven cases who made a transition to psychosis had no significant differences in P300
amplitude/latency or N100 amplitude/latency (p values ranging from 0.30 to 0.63 for all four 
analyses). We have reported these comparisons very concisely and cautiously because referee #2 
said that these analyses with only 7 individual making a transition were preliminary and power is 
limited. Please see results section paragraph 2.
RESPONSE TO REVIEWER #2: 
Thank you for your suggestions, which have improved the paper. Below are your comments in 
blue-italics and how we have amended the manuscript accordingly in black with cross-references 
to the revised manuscript.
This paper addresses an important and timely topic, namely, whether auditory P300 is reduced in 
subjects with at risk mental states and whether the P300 predicts subsequent conversion to 
psychosis.  The study finds a significant deficit in P300 in ARMS subjects, relative to controls, 
replicating a previously a previously published report.  The study had the potential to incrementally 
* 2. Response to Reviews
2contribute to the literature by examining the utility of baseline P300 deficits as a predictor of 
subsequent conversion to psychosis; however, the negative finding coupled with the lack of power 
for this analysis (only 7 converters) make this aspect of the study inconclusive.   More detailed 
comments are provided below:
We have added a paragraph in the discussion to acknowledge the limitation of our small group of 
converters and how we have low statistical power to compare them against those remaining at 
risk. This is also mentioned in the conclusion.
Please note that referee #1 requested we do undertake a preliminary comparison of converters 
versus non-converters in demographics as well as P300 and N100. We reported this in the results 
section very concisely (paragraph 2); although we acknowledge this is inconclusive (discussion 
paragraph 6 dealing with study limitations).
1. The introduction fails to distinguish P300 elicited by task-relevant target stimuli, sometimes 
referred to as "P3b", from P300 elicited by task-irrelevant infrequent novel or salient stimuli, 
sometimes referred to as "P3a".  The current study only examines the auditory target P3b, a 
subset of possible P300 measures that one might choose to study in At-Risk Mental State 
subjects.  It is important to make these distinctions in order for readers unacquainted with the 
P300 literature to understand the nature of this ERP component and the limits of the 
generalizability of the current study.
We have now made the distinction between the two P300 sub-components and their nature very 
clear both in the introduction (paragraph 1 and briefly in paragraph 2) and also in the discussion
(paragraph 4).
2.  This study lacks a schizophrenia comparison group, making it difficult to place the deficit 
observed in the ARMS group into perspective within the illness course of schizophrenia.  In other 
words, the current study design does not allow any statements about whether the P300 deficits 
observed are similar or attenuated relative to schizophrenia patients at their first episode of illness.  
This design limitation does not invalidate the results, but it does limit the ability to make inferences 
regarding P300 as trait marker of illness vulnerability versus a pathophysiological marker of illness 
progression during transition to psychosis.  This limitation should be mentioned in the discussion.
We acknowledge this limitation in our study. A direct comparison of controls, high-risk and first 
episode patients would have been ideal. We included an additional paragraph in the discussion to 
report this and other limitations (paragraph 6 in discussion).
We published a meta-analysis of patients with schizophrenia (Bramon et al., 2004b) and of 
unaffected relatives (Bramon et al., 2005). These were the pooled standardized effect sizes 
(PSES) obtained:
PSES patients v controls: 0.85 (95% CI: 0.65 to 1.05; p < 0.001)
PSES relatives v controls: 0.61 (95% CI: 0.30 to 0.91; p <0.001).
PSES calculated above as Cohen’s d (Cohen, 1969) allow a direct comparison of the strength of an 
effect. In this present study the standardized difference between at-risk subjects and controls at
centro-parietal sites (averaging CZ and PZ measures as in the meta-analysis) is 0.49. This would 
indicate that the deficits found in cases at-risk due to prodromal symptoms are less severe than
those reported for chronic patients but fall within the confidence interval of the deficits described in 
3populations with genetic risk, such as the unaffected first degree relatives of patients. We thought it 
would improve the paper to mention this briefly in the discussion.
3.  The EEG/ERP methods are inadequately described.   Although we are told that the data were 
epoched and baseline corrected, we are not told the length of the epochs nor the length of the 
baseline period subtracted from the epochs.  The authors mention that they applied the 
Neuroscan's ocular correction algorithm, but they do not mention whether epochs were rejected 
when they contained a voltage value exceeding some criterion (a step that is commonly referred to 
as "artifact rejection").  Were the EEG epoch data subject to artifact rejection?  If so, this should be 
explicitly described.
We intended to write a brief report and refer readers to our previous papers for further details. 
However, as requested, we have now amended the manuscript to have a complete EEG 
methodology section. 
Neuroscan have an artifact rejection procedure where epochs containing a voltage value above a 
chosen value are automatically excluded; however this can lead to substantial data loss. Also, if a 
group systematically blinks more (as may happen in patients on antipsychotic and other
medication) this could lead to bias. We therefore use another ocular artifact rejection procedure,
also available in Neuroscan, where the effect of blinks is minimized by linear regression methods
and all epochs collected can be used. A template of blinks is obtained for each individual (and 
each experiment they did) and this is used to obtain coefficients and apply corrections to all other 
channels. This is a well-known procedure developed by Semlitsch (Semlitsch et al., 1986) and that 
we have used in several of our previous papers successfully (Bramon et al., 2004a; Bramon et al., 
2006; Bramon et al., 2005; Hall et al., 2007a; Hall et al., 2007b; Hall et al., 2006a; Hall et al., 
2006b; Hall et al., 2004; Schulze et al., In press).
4.  The authors state that the EEG signal was digitized at 500 Hz with a bandpass filter of .05 to 
200 Hz.  Although the Nyquist rule stipulates that signals need to be sampled at least twice as fast 
as the highest frequency of interest in order to avoid aliasing, Neuroscan Synamps amplifiers 
usually implement a more stringent rule, requiring a sampling rate of 4 times the highest frequency 
of interest as defined by the low pass filter setting.  Did the authors use Neuroscan amplifiers?  If 
so, they should confirm that they were able to digitize the EEG signal at 500 Hz with a 200 Hz low 
pass filter setting.  At least using older Synamps amplifliers, this would not have been possible.
Many thanks for spotting this. The sampling rate used in this sample was 1000 Hz. This is now 
corrected in the methods. We used a Neuroscan Synamps amplifier purchased in 2003 and as you
suggest this uses a more stringent Nyquist rule. 
5.  It is not clear why the authors only examined the N100 to the standard stimulus.  The N1 to 
standards can be rather attenuated due to the lack of sufficient time between auditory stimulus 
presentations to allow full recovery of the N100 neural generators.  The N100 to the target stimuli 
do not suffer from this recovery constraint because they are well separated in time.  Moreover, 
N100 can be augmented by attention, further motivating an analysis of the N100 elicited by the 
auditory target stimuli.  Addition of this analysis would strengthen the paper.
We reported the N100 to standard stimuli because with 320 of them we get a better signal to noise 
ratio. We have now added the analyses of N100 response to rare tones (see results section) and 
we have amended the methods section accordingly. As for the frequent tones, there were no 
significant differences in N100 to the rare tones between cases at risk and controls. Thus the main 
findings of the paper remain the same. Because we have had to go back to the original waveforms
4and do further signal processing and statistical analyses it has taken us some time to get back with 
the amended manuscript.
6.  An exclusion criterion for the healthy controls, but not the at risk patients, was alcohol or drug 
abuse or dependence in the past 12 months.  This introduced a confound in the group 
comparison, since the at risk subjects used illicit drugs significantly more than the healthy controls.  
How can the authors be sure that the group differences they observed are due to the at-risk 
mental state rather than their increased rate of drug use?  Moreover, inclusion of drug use history 
as a covariate in the model is problematic when the groups differ on the covariate (See Miller and 
Chapman, 2001, "Misunderstanding analysis of covariance", J of Abnormal Psychology).  A better 
strategy would have been to match the groups on drug use.
The exclusion criteria were misreported in the original manuscript and we have amended the
methods section to fully clarify that: (i) A DSM-IV diagnosis of alcohol or drug abuse or 
dependence was an exclusion criterion for all participants and while the patients were referred to a 
specialist addictions service controls were simply screened out. (ii) However, recreational 
substance use (alcohol or illicit drugs) not reaching DSM-IV criteria for dependence/abuse were 
not an exclusion criteria and that’s again for all participants. The reason for this was to avoid 
recruiting a sample of “super-healthy” participants that could not be generalized to the population 
we are studying (young inner-city London dwellers where recreational drug usage is very 
prevalent). Despite using the same inclusion/exclusion criteria in the end our groups were not well 
matched for recreational drug usage and the cases were significantly more likely to report having 
recreational use than the controls. It is also important to remember that drug usage for this study 
relied only on self-report and this has important limitations (compared to urine drug screening). In 
addition, drug usage could well be regarded as a mediating factor rather than a confounder. In any 
case, we accept this criticism and, since our data collection is ongoing, we will endeavor to 
improve the group matching for drug use in future.
As you requested and based on Miller and Chapman 2001, we have re-analysed the study 
without including the drug effect variables and the paper is now amended to report these 
final statistics. The findings of the paper have not changed. We have also addressed the 
issue of drugs in the discussion. Finally, we’d like to highlight that confound from 
prescribed medication is a much more serious problem in this type of case control 
research and our sample was un-medicated and mostly naïve to psychotropics. 
Due to the lack of matching in recreational drug usage, we have run additional analyses examining
a group X drug use interaction as well as a main effect of drugs in all the paradigms studied
and no significant interaction or main effects were found. The estimated differences varied slightly 
but the findings of the study were unchanged (there still was a significant effect of group 
(case/control) on P300 amplitude but not on P300 latency, N100 amplitude or N100 latency). All of 
this indicates that the findings in this study (most of them negative actually) are not confounded by 
recreational drug usage. Please see all the analyses in an appendix at the end of this letter.
7.  In light of the fact that data were collected from a 64 channel scalp montage, it was 
disappointing that only midline electrodes Fz, Cz, and Pz were analyzed.  Moreover, the analysis 
approach was rather unconventional, apparently treating these three electrodes as a vector of 
correlated dependent measures.  It is more common, and probably more useful, to include 
electrodes from sites across the scalp in the analysis, and to explicitly include scalp topography 
factors in the analysis model.  This would allow the authors to examine whether the groups 
showed differences in the scalp topographies of their P300 (or N100) amplitudes and/or latencies.  
5This is particularly important because a number of prior studies have suggested that P300 shows 
a left-lateralized deficit over temporal scalp sites in schizophrenia patients, a finding that has been 
linked to MRI volume deficits of the left superior temporal gyrus in these patients.
As requested we have now examined temporal channels for the P300 wave. We have added a 
paragraph in the results section to report topographic changes both in P300 and N100 in our study
(last paragraph) and in the discussion we also address the issue of lateralization of the P300
deficits (3rd paragraph). 
Most of the P300/N100 literature treats FZ, CZ and PZ as independent measures and report at 
these three locations only. Our statistics colleagues advised analyzing the data in one model, 
where we take into account that neighboring electrode measures are not really independent but 
rather have strong correlations (with coefficients between 0.7 and 0.9). We have published similar 
analyses already in Bramon et al, 2005; Bramon et al, 2006; Schulze et al, 2007.
We agree that the analysis you suggest using electrodes across the scalp including full head
topography factors is ideal. However, having collected 64 channels it is extremely complex to 
execute and to interpret. Other referees may have criticized us given that our sample is of modest 
size (almost as many electrodes as participants). Thus, given the size of our prodromal sample, 
we have focused on midline and temporal areas in this paper. We are working to develop the type 
of analysis you suggest and hope to apply it to our larger datasets.
8.  Age was apparently used a covariate in their statistical mode of P300 and N100 effects.  It is 
not clear whether age x group interactions were included or ruled out in their analysis model.  The 
question is whether age relationships with P300 amplitude or latency showed different slopes in 
the two subject groups, and whether homogeneity of slopes was an implicit assumption of their 
model.  This needs to be clarified.
All our analyses looking at the effect of group on ERPs were adjusted by age as a covariate. This 
is because several studies and in particular a meta-analysis have found that there is an effect of 
ageing on P300 especially on its latency which tends to increase in older ages (Polich, 1996). We 
thought it would be reasonable to adjust our N100 by age too. 
We also examined group x age interactions systematically, which were not significant for any of 
the paradigms examined. In addition the age range of our sample is very narrow (16-35 years) and 
the two groups did not have significant age differences. 
We have amended the final methods section to clarify how we looked at covariates and at
interactions. We’ve also amended the last paragraph of the results section so that this issue of the 
demographic comparisons is clearer.
9.  We are told in the results that there were no significant performance differences between the 
groups in the oddball task.  This conclusion is limited to the accuracy data.  Were there reaction 
time differences between the groups?
The data on reaction time has now been added. Independent sample t-tests indicate that, 
compared to controls, people at risk for psychosis had similar reaction times. These findings have 
been briefly added to the results (end of 1st paragraph) and the discussion (4th paragraph). This 
has required going back to our original files and has taken some time for processing.
612.  In the results, the authors state: "We found a significant effect of group on P300 amplitude, 
with lower amplitudes in cases at risk than in controls (Coef.= -3.4 microvolt; 95%CI: -5.7 to -1.1; 
p<0.01)."  What is this coefficient? How is it interpreted?  Is this the predicted or estimated group 
effect?
Please note your comments jump from point 9 to 12. We have not received anything else from the 
journal. The interpretation of this linear regression un-standardized coefficient is that as you move 
from controls to at risk cases there is a reduction (negative coefficient) of 3.4 microvolt. This is an 
estimated effect with a 95% CI -5.7 to -1.1, which is significant. We have amended the results 
section so that this is clearer and rather than using the term “coefficient” we now call this 
“Estimated difference”. Please note that as we have re-analyzed the whole study to drop the 
effects of illegal drugs the coefficients for group differences have changed slightly (although the 
findings of the paper remain unaltered). 
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APPENDIX – P300 AMPLITUDE ANALYSES ADJUSTED BY THE MAIN EFFECT OF 
DRUGS AND BY DRUGxGROUP INTERACTIONS
*GROUP is the main variable of interest
*DRUGS is the main effect of drugs defined as a dichotomous variable 
(recreational use of drugs yes or no).
*GxD is the group by drugs interaction term.
. iis id (this accounts for the three observations per participant)
. xi: xtreg  p300amp  group  age  sex  drugs  i.channel  gxd, mle
i.channel         _Ichannel_0-2       (naturally coded; _Ichannel_0 omitted)
Fitting constant-only model:
Iteration 0:   log likelihood = -921.65231
Iteration 1:   log likelihood = -898.56512
Iteration 2:   log likelihood = -893.60016
Iteration 3:   log likelihood = -893.18875
Iteration 4:   log likelihood = -893.18426
Fitting full model:
Iteration 0:   log likelihood = -811.49141
Iteration 1:   log likelihood = -810.92254
Iteration 2:   log likelihood = -810.90547
Iteration 3:   log likelihood = -810.90546
Random-effects ML regression                    Number of obs      =       276
Group variable (i): id                          Number of groups   =        92
Random effects u_i ~ Gaussian                   Obs per group: min =         3
                                                               avg =       3.0
                                                               max =         3
                                                LR chi2(7)         =    164.56
Log likelihood  = -810.90546                    Prob > chi2        =    0.0000
------------------------------------------------------------------------------
     p300amp |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
       GROUP |  -3.133597   1.193447    -2.63   0.009    -5.472711   -.7944828
         age |   .2347704   .1128663     2.08   0.038     .0135566    .4559843
         sex |   1.710268    1.03536     1.65   0.099    -.3189993    3.739535
8       DRUGS |   6.442982   4.918535     1.31   0.190    -3.197169    16.08313
  Channel CZ |   5.510317   .4973753    11.08   0.000     4.535479    6.485155
  Channel PZ |   7.135006   .4973753    14.35   0.000     6.160168    8.109843
         GxD |  -5.334248   5.217364    -1.02   0.307    -15.56009    4.891598
       _cons |  -.0032421   2.879655    -0.00   0.999    -5.647263    5.640779
-------------+----------------------------------------------------------------
    /sigma_u |   4.427319   .3921001                      3.721818    5.266553
    /sigma_e |   3.373364   .1758487                      3.045729    3.736243
         rho |   .6326884   .0500865                      .5312293    .7256148
------------------------------------------------------------------------------
Likelihood-ratio test of sigma_u=0: chibar2(01)=  109.05 Prob>=chibar2 = 0.000
-------------------------------------------------------------------------------
Dropping the GxD interaction term as well as the main effect of DRUGS as these 
are not significant and as advised by referee we are left with the findings 
reported in the paper
.iis id
. xi: xtreg  p300amp  group  age  sex  i.channel, mle
i.channel         _Ichannel_0-2       (naturally coded; _Ichannel_0 omitted)
Fitting constant-only model:
Iteration 0:   log likelihood = -923.94638
Iteration 1:   log likelihood = -899.27156
Iteration 2:   log likelihood = -893.69728
Iteration 3:   log likelihood = -893.19091
Iteration 4:   log likelihood = -893.18426
Fitting full model:
Iteration 0:   log likelihood = -812.29373
Iteration 1:   log likelihood = -811.95089
Iteration 2:   log likelihood = -811.94539
Random-effects ML regression                    Number of obs      =       276
Group variable (i): id                          Number of groups   =        92
Random effects u_i ~ Gaussian                   Obs per group: min =         3
                                                               avg =       3.0
                                                               max =         3
                                                LR chi2(5)         =    162.48
Log likelihood  = -811.94539                    Prob > chi2        =    0.0000
------------------------------------------------------------------------------
     p300amp |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
-------------+----------------------------------------------------------------
       GROUP |  -2.932581   1.066861    -2.75   0.006     -5.02359    -.841573
         age |   .2406552   .1140261     2.11   0.035     .0171682    .4641422
         sex |   1.519467   1.038355     1.46   0.143    -.5156714    3.554605
  Channel CZ |   5.510317   .4973388    11.08   0.000     4.535551    6.485083
  Channel PZ |   7.135006   .4973388    14.35   0.000     6.160239    8.109772
       _cons |   .0759236   2.908449     0.03   0.979    -5.624532    5.776379
-------------+----------------------------------------------------------------
    /sigma_u |   4.487321   .3955848                      3.775275    5.333666
    /sigma_e |   3.373364   .1758164                      3.045786    3.736173
         rho |   .6389226   .0495039                      .5384387    .7306103
9------------------------------------------------------------------------------
Likelihood-ratio test of sigma_u=0: chibar2(01)=  111.70 Prob>=chibar2 = 0.000
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Individuals with an ‘At Risk Mental State’ (ARMS) experience ‘prodromal’ symptoms and previous 
studies report that between 20 and 40% of them make a transition to psychosis within one or two 
years (Addington et al., 2007; Broome et al., 2005a; Klosterkotter et al., 2001; McGlashan et al., 
2007; McGlashan et al., 2004; Morrison et al., 2002; Olsen and Rosenbaum, 2006; Schultze-Lutter et 
al., 2007; Yung et al., 2007; Yung et al., 2003; Yung et al., 2004). The basis of the vulnerability to 
psychosis in this group is unknown and, whilst evidence shows that psychological and 
pharmacological interventions improve outcomes (Bechdolf et al., 2005; McGorry et al., 2002; Miller 
et al., 2003; Phillips et al., 2005; Ruhrmann et al., 2005; Woods et al., 2003), treating high risk 
subjects remains controversial since most of them are not destined to develop the disease (Broome et 
al., 2005b; Cornblatt et al., 2001; Haroun et al., 2006). The identification of biological measures 
associated with a subsequent transition to psychosis would help to target early treatment to those who 
require it (Bender et al., 2007; Bramon et al., 2004a; Eastvold et al., 2007; Mason et al., 2004; 
Pantelis et al., 2003; Simon et al., 2007; van der Stelt and Belger, 2007).
Neurophysiology provides a non-invasive method to evaluate brain function related to cognitive and 
perceptual processes in vivo. The P300 wave reflects cortical activity during a form of continuous 
performance task in which subjects respond to target stimuli embedded at random in a sequence of 
standard stimuli. This event-related potential is more specifically known as the P3b in order to 
distinguish it from the P3a, a response to task-irrelevant novel infrequent stimuli not examined in this 
paper (Araki et al., 2006; Frodl-Bauch et al., 1999; Laurens et al., 2005; Mathalon et al., 2000; 
Salisbury et al., 2004; Salisbury et al., 2001; Sponheim et al., 2006). Another EEG marker
investigated here, the N100 wave, reflects the early phase of attentive stimulus processing (Boutros et 
al., 2004; McCarley et al., 1991). 
A meta-analysis of studies over the last decade indicates that the amplitude of the P300 (the P3b
wave) is severely reduced and its peak is substantially delayed in patients with schizophrenia (Bramon 
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et al., 2004b). Qualitatively similar, but less severe, deviances in amplitude and latency are also 
evident in the non-psychotic relatives of patients with schizophrenia (Blackwood et al., 1991; Bramon 
et al., 2005; Bramon et al., 2004b; Frangou et al., 1997). P300 deviances may thus constitute markers 
of a genetic predisposition to develop/transmit psychosis (Ahveninen et al., 2006; Braff et al., 2007; 
Bramon et al., 2006; Calkins et al., 2007; Cannon and Keller, 2006; Golimbet et al., 2006; Gottesman 
and Gould, 2003; Hall et al., 2006a; Hall et al., 2006b; Mulert et al., 2006; Price et al., 2006; Schulze 
et al., In press; Sumich et al., 2006; Sumich et al., 2007; Turetsky et al., 2007). Some, but not all, 
previous studies show N100 amplitude reductions in schizophrenic patients (Ahveninen et al., 2006; 
Brown et al., 2002; Frangou et al., 1997; Heinks-Maldonado et al., 2007; Javitt et al., 2000; Kogoj et 
al., 2005; O'Donnell et al., 2004; Pfefferbaum et al., 1984; Roth et al., 1981; Roth et al., 1980; Shelley 
et al., 1999; Sumich et al., 2006; Sumich et al., 2007; Winterer et al., 2001) but the N100 wave has 
not been examined in populations with high risk of developing psychosis.
Van der Stelt et al (van der Stelt et al., 2005) were the first to report P300 amplitude reductions in 
prodromal cases, which were of similar severity to those found in patients with recent onset as well as 
chronic schizophrenia. We set out to replicate this finding and to examine other EEG markers such as 
the N100 wave in an independent sample.
METHODS AND MATERIALS
Subjects were 35 people with an at risk mental state according to criteria established by Yung and 
colleagues, which include people with sub-clinical “attenuated” psychotic experiences, individuals 
with psychotic symptoms of insufficient duration to reach a diagnosis (brief limited intermittent 
psychotic symptoms known as BLIPS), and finally individuals with a schizotypal personality disorder 
or with a first-degree relative with psychosis who had a significant decline in function (Yung et al., 
2005). These were compared against 57 healthy volunteers with no family or personal history of 
psychotic disorders. At risk subjects were recruited through the clinical service “Out-reach And 
Support In South London”(OASIS) (Broome et al., 2005a). Controls were recruited from the same 
geographical area by advertisements in the local press. Participants were excluded if they had 
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neurological disorders, or head injury with loss of consciousness longer than ten minutes or a DSM-
IV diagnosis of alcohol or illegal substance dependence or abuse in the 12 months prior to
assessment. Alcohol and other substance use, not reaching criteria for dependence or abuse, did not 
constitute exclusion criteria to ensure the sample was representative of our population. Of the thirty 
five cases at risk all but three were antipsychotic naïve and none of them were taking antipsychotics at 
the time of EEG testing. None of the controls were on any psychotropic medication at the time of 
EEG testing. All participants gave written informed consent to enter the study. This research was 
approved by the Ethical Committee at the Institute of Psychiatry.
Clinical assessments: All participants were interviewed to collect information on socio-demographic, 
physical and mental health data and the timing and nature of any symptoms. The instrument used to 
identify at risk cases was the Comprehensive Assessment of At-Risk Mental States (CAARMS)
(Yung et al., 2005). The Family Interview for Genetic Studies (Nurnberger et al., 1994) was used to 
obtain/rule out any psychiatric diagnoses in the participant’s first and second degree relatives.
Transition to psychosis was defined using the threshold criteria in the CAARMS (Yung et al., 2005).
P300 paradigm: The P300 and N100 were obtained with a standard auditory oddball paradigm
(Bramon et al., 2005). Stimuli were four hundred 80 dB tones, with a 2 (± 0.2) seconds inter-stimulus 
interval presented through bilateral intra-aural earphones. 80% of the tones were ‘non-targets’ of 1000 
Hz and 20% were ‘targets’ of 1500 Hz in a random sequence. Subjects were instructed to keep their 
eyes open and press a button in response to target tones only. EEG data were collected from 64 scalp 
sites according to the 10/20 International System (Jasper, 1958) and were grounded at Fpz using 
syntered electrodes in a cap. Bilateral mastoids served as reference and vertical and horizontal electro-
oculographs monitored eye movements. Data were continuously digitised at 1000 Hz with a 0.05 to 
100 Hz band-pass filter (24 dB/octave roll-off). Impedances were kept below 5 KOhms. A Neuroscan 
linear regression procedure was employed to minimise ocular artifacts (Semlitsch et al., 1986). The 
continuous EEG recording was epoched (-100 to 700 ms), baseline corrected using the pre-stimulus 
interval (-100 to 0 ms), band-pass filtered 0.05 to 45 Hz and averaged for targets and non-targets 
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separately (Bramon et al., 2005; Frangou et al., 1997).  The P300 was defined as a positive waveform 
generated by the target tones and peaking between 280-500 ms post-stimulus. The N100 was defined 
as the first negative wave peaking between 60 and 140 ms. The N100 wave was analysed for both 
frequent and rare tones (Brown et al., 2002) and the statistical details are reported for the rare tones 
by default and for frequent tones wherever relevant as stated in the text. P300 and N100 peak 
amplitudes and latencies were measured using a computer algorithm, which made the process blind to 
group affiliation.
Statistical analysis: The socio-demographic characteristics and task performance between groups 
were compared using χ2 for categorical and t-test for continuous variables. The P300 and the N100 
waves were compared between cases at risk and healthy controls using linear mixed models fitted
with maximum likelihood methods. FZ, CZ and PZ measures were analysed and the correlations 
between these electrodes within each individual were accounted for by including random intercepts 
for participants. This is needed to maintain correct type-1 error rates (for similar two-level or three-
level nested models see (Bramon et al., 2006; Bramon et al., 2005). The P300 amplitude was the
dependent variable and group (at risk or control), electrode (FZ, CZ, PZ), sex and age were the 
independent variables. We examined interactions of group by sex, group by age and group by
electrode. Similar analyses were conducted with P300 latency, N100 amplitude and N100 latency as 
dependent variables.  For the P300 wave only, an additional analysis tested the group differences 
comparing left and right temporal electrodes (T7 and T8 respectively) again adjusting by age and sex 
and relevant interactions. Boxplots were used to examine departures from normality and none were 
detected. All analyses were conducted in STATA 9.2 using the xtreg and xtlogit commands for 
regression analysis adjusting for clusters (electrode measures) in the data.
RESULTS
This sample included 35 cases with at risk mental states (ARMS) as defined by Yung and colleagues
(Yung et al., 2005) as well as 57 healthy volunteers. As can be seen in table 1, the two participant
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groups were similar in demographics including age, sex, ethnicity and education. Subjects with at risk 
mental states were significantly more likely to report recreational drug use (p<0.001) and also smoked 
significantly more cigarettes per day (p<0.01). Of the at risk group, 66% suffered attenuated sub-
threshold psychotic symptoms, 11% had brief limited intermittent psychotic symptoms (BLIPS), 
another 3% were included because of having a schizotypal personality or a family history of psychosis 
in addition to functional decline. Finally, 11% had both attenuated and BLIPS symptoms and 9% 
fulfilled both attenuated and trait and state criteria. 
There were no significant differences between groups in terms of task accuracy or speed. Thus correct 
responses were 99.0% ±2.0% for controls and 98.9% ±1.9% for the at risk group. Reaction times for 
the button press were 0.48 ±0.21 and 0.50 ±0.16 seconds in controls and at risk people respectively.
Table 1 about here
Two at risk participants disengaged from the service shortly after inclusion and their clinical outcome 
is unknown. These drop outs belonged to the attenuated symptoms category and did not differ in 
socio-demographic characteristics from those followed up successfully. Of the remaining 33 
participants, after an average follow up of 23.5 months (range 1.6 to 46.8; SD 13.5 months), seven 
subjects (21.2%) developed a full-blown psychotic episode. Amongst the cases at risk the mean GAF 
score at the end of the follow up period was 71.1 (range 40 to 90; SD 14.2). Compared to the cases 
remaining at risk, the seven individuals making a transition to psychosis did not differ significantly in 
age, sex, ethnicity, education or in their P300 or N100 amplitudes and latencies.
Cross-sectional comparison between “At risk” cases and controls in event related potentials:
We found a significant effect of group on P300 amplitude, with lower amplitudes in cases at risk than 
in controls (Midline estimated difference= -2.9 microvolt; 95%CI: -5.0 to -0.8; p<0.01. Temporal 
channels Est. Dif.= -1.6 microvolt; 95%CI: -3.1 to -1.0; p=0.04).  The two groups did not differ 
significantly in P300 latency, N100 amplitude and N100 latency (both frequent and rare tones were 
Bramon, et al.
7
examined for N100). 
Topographic effects: 
The P300 amplitude was largest and its latency most delayed at parietal compared to frontal sites (Est. 
Dif. amplitude PZ-FZ= 7.1 microvolt; 95%CI: 6.2 to 8.1; p<0.01. Est. Dif. latency PZ-FZ= 23.7 
milliseconds; 95%CI: 14.0 to 33.4; p<0.01). The P300 amplitude was larger at left temporal than right 
temporal electrodes in both cases and controls (T7-T8 Est. Dif.= 0.9 microvolt; 95%CI: 0.03 to 1.8; 
p=0.04). The group by temporal region interaction was not significant suggesting no evidence of 
lateralisation in the P300 amplitude deficits observed in our at-risk cases. The P300 latency showed 
no differences between left and right temporal regions. Finally, the N100 amplitude was larger (in 
absolute value) and its latency greater at frontal than parietal electrodes (Est. Dif. amplitude PZ-FZ= 
3.8 microvolt; 95%CI: 3.4 to 4.2; p<0.01. Est. Dif. latency PZ-FZ= -13.3 milliseconds; 95%CI: -17.1
to -9.5; p<0.01).
Demographic variations: 
There were no significant findings for the P300 wave except for ageing, which marginally increased 
P300 amplitudes (Est. Dif= 0.24 microvolt; 95%CI: 0.02 to 0.46; p=0.04). As for the N100 amplitude, 
in this sample women had a significantly greater amplitude than men (Est. Dif.= -1.2 microvolt; 
95%CI: -2.2 to -0.2; p=0.02). Men had delayed N100 latencies compared to women (Est. Dif.= -8.1
ms; 95%CI: -13.7 to -2.4; p<0.01). Ageing was associated with delayed N100 latency to the frequent 
tones (Est. Dif.= 0.6 ms; 95%CI: 0.1 to 1.2; p=0.02); however, this effect did not reach statistical 
significance for the N100 to the rare tones. Given the size of our sample and its narrow age range
these minor demographic differences need to be taken with caution. Finally, there were no significant 
interactions of group with age, sex and topography covariates for any of the waves examined. Figures
1 and 2 provide further details about group comparisons in P300 and N100 performance.
Figure 1 about here




Our hypothesis, that the P300 in subjects with an at-risk mental state (AMRS) would differ from that 
in healthy volunteers, was confirmed, with its amplitude significantly reduced in the ARMS group. 
From twin studies we know that P300 traits are reliable and heritable (Hall et al., 2006a; Hall et al., 
2006b; Hall et al., 2004; van Beijsterveldt and van Baal, 2002). P300 amplitude reductions as well as 
latency delays constitute markers of vulnerability for psychosis, as they are evident in the unaffected 
relatives of patients (Blackwood et al., 1991; Bramon et al., 2005; Bramon et al., 2004b; Frangou et 
al., 1997; Pierson et al., 2000; Turetsky et al., 2000; Winterer et al., 2003) and they show a significant 
genetic correlation with schizophrenia and bipolar disorder (Hall et al., 2007a; Hall et al., 2007b).
As for the topography, the P300 amplitude deficits in the at-risk cases were consistently observed in 
midline as well as temporal sites (McCarley et al., 1991; McCarley et al., 2002; Morstyn et al., 1983). 
However, we found no evidence that these deficits were left-lateralized and this could be due to our 
paradigm involving a button press; which is thought to diminish the abnormal P300 asymmetry in 
schizophrenia (Ford et al., 1994; Pfefferbaum et al., 1989; Renoult et al., 2007; Salisbury et al., 2001).
While ageing and task difficulty are known to influence P300 performance, especially its latency
(Mori et al., 2007; Polich, 1996); demographic confounders are unlikely to explain our findings and 
all analyses were adjusted for age and sex. Use of cannabis and other drugs is a known risk factor for 
psychosis (Arseneault et al., 2004) and since the at-risk group reported recreational drug consumption
more often than the controls this could have contributed to our findings. However, additional analyses 
(available from the authors upon request) show that in this sample illicit drug use had no significant
main effect on the P300 amplitude or any of the other paradigms examined and that there were no 
significant group by drug use interactions. Finally, since all but three of the ARMS subjects were 
naïve to antipsychotic medication, and no subject was on antipsychotics at the time of EEG testing,
the reduction in P300 amplitude is unlikely to be confounded by pharmacological treatment (Laurent 
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et al., 1999). Our findings are consistent with the data from two previous smaller studies of the P300 
in the ARMS, both of which reported reductions in amplitude (Mathalon et al., 2004; van der Stelt et 
al., 2005).
The P300 wave is associated with a task that involves attentional processing and a degree of executive 
functioning. An abnormal P300 in the ARMS is thus consistent with data from neuropsychological 
studies of this group, which suggest that the ARMS is associated with impaired performance on tasks 
that engage attention (such as the CPT) and executive processes (Brewer et al., 2005; Cornblatt et al., 
2004; Lencz et al., 2006; Pukrop et al., 2007; Woods et al., 2003). Our findings are also consistent 
with data from a functional imaging study of the P300 which indicated that subjects with an at-risk 
mental state showed less activation in the temporal cortex than controls but more than patients with 
schizophrenia (Morey et al., 2005).  Interestingly, whilst the at-risk cases showed normal accuracy 
and reaction time in the P300 task at a behavioral level, their cortical physiology was impaired.
Increasing task difficulty and using multi-modal techniques (Bender et al., 2007; Molina et al., 2007; 
Price et al., 2006; Sponheim et al., 2006) should increase our ability to detect subtle cognitive changes 
in the prodrome of psychosis.
Like Van der Stelt et al (van der Stelt et al., 2005) we failed to find latency deficits in the ARMS 
group. Because individuals at increased genetic risk of schizophrenia consistently show moderate 
latency delays (Bramon et al., 2005), we expected a similar finding in populations at clinical risk. 
However, both available studies may lack statistical power and thus P300 latency deficits can not be 
ruled out until larger samples can be examined. Furthermore, our paradigm as well as Van der Stelt’s
only allows us to examine the P3b wave (a response elicited by the target stimuli that require a 
response from the subject). More complex P300 experiments incorporating additional infrequent 
novel stimuli that generate the P3a response would be worth investigating in the prodrome (Araki et 
al., 2006; Frodl-Bauch et al., 1999; Laurens et al., 2005; Mathalon et al., 2000; Salisbury et al., 2004; 
Salisbury et al., 2001; Sponheim et al., 2006; Sumich et al., 2007).
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A limitation of this study is that we lacked a sample of patients with schizophrenia to compare with 
our at-risk and control groups. Similarly, since only seven of our cases at risk converted to psychosis 
we do not have sufficient statistical power to compare them against those who remained at risk after 
follow up. Meta-analyses show that, compared to controls, P300 amplitude deficits are moderate-
severe in chronic patients with schizophrenia with a pooled standardised effect size calculated as 
Cohen’s d of 0.85 (95% CI: 0.65 to 1.05; p < 0.001) and of moderate severity in their unaffected 
relatives with a pooled standardised effect size of 0.61 (95% CI: 0.30 to 0.91; p <0.001) (Bramon et 
al., 2005; Bramon et al., 2004b; Cohen, 1969). Pooled standardised effect sizes as calculated above
allow a direct comparison of the strenght of effects (Cohen, 1969). In this present study the 
standardized difference between at-risk subjects and controls at centro-parietal sites (averaging CZ 
and PZ measures as in the meta-analysis) was 0.49. These data suggest that the deficits found in cases 
at-risk due to prodromal symptoms are less severe than those reported for chronic patients but, since 
they fall within the confidence interval, are comparable to the deficits described in populations with 
genetic risk, such as the unaffected first degree relatives of patients. However, direct comparisons,
ideally with first episode patients, and especially longitudinal studies are needed to confirm this 
finding.
As an abnormal P300 is thought to reflect increased genetic risk for schizophrenia, this is compatible
with the view that the high risk of psychosis in the ARMS may have a genetic basis. While only a 
minority of subjects in most ultra-high risk samples, including our own, have a known family history 
of psychosis, subjects could still be carrying risk alleles of genes that predispose to psychosis. Indeed, 
the attenuated psychotic symptoms that are characteristic of at-risk mental state populations were also 
described in approximately 50% of young adults who had a first degree relative with schizophrenia; 
and those young relatives who had additional high levels of schizotypy had a risk of developing 
psychosis comparable to the ARMS group (Johnstone et al., 2005). Both the relatives of patients with 
schizophrenia and individuals with an ARMS show neuropsychological and volumetric MRI 
abnormalities that are qualitatively similar to those seen in schizophrenia but are quantitatively less 
severe (Brewer et al., 2005; Woods et al., 2003). To date no studies of genetic factors in the ARMS 
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have been completed, but these are ongoing and may clarify the contribution of genes to the 
vulnerability to psychosis in this group (Bender et al., 2007). 
Neither the amplitude nor the latency of the N100 wave was abnormal in our ARMS group. 
Amplitude reductions and latency delays of the N100 wave have been described in chronic 
schizophrenia (Frangou et al., 1997; Karoumi et al., 2000; O'Donnell et al., 2004; Wood et al., 2006), 
but have not been evident in the non-psychotic relatives of patients (Frangou et al., 1997; Karoumi et 
al., 2000). To our knowledge, this is the first examination of N100 performance in the at-risk mental 
state. The existing evidence, although more limited than that for P300, indicates that the N100 deficits 
are not markers of risk but rather a correlate of chronic psychotic symptoms (Brown et al., 2002; 
Javitt et al., 2000; Kogoj et al., 2005; O'Donnell et al., 2004; Roth et al., 1980; Shelley et al., 1999; 
Sumich et al., 2007).
As for clinical outcomes after an average of two years follow up, the rate of transition in our sample 
was lower than in early studies of the ARMS, but there is considerable variation across centres, 
reflecting different populations and ascertainment methods (Addington et al., 2007; Broome et al., 
2005a; Klosterkotter et al., 2001; McGlashan et al., 2007; McGlashan et al., 2004; Olsen and 
Rosenbaum, 2006; Schultze-Lutter et al., 2007; Yung et al., 2007; Yung et al., 2003; Yung et al., 
2004), and a rate of 21% is in line with that reported in recent work from comparable populations in 
the UK (Morrison et al., 2002).
In summary, our data and a previous smaller study (van der Stelt et al., 2005) both indicate that the at-
risk mental state is associated with a significant reduction in the amplitude of the P300 wave, possibly 
reflecting an underlying genetic predisposition. A longitudinal analysis examining whether P300 and 
other biological markers at baseline can help to predict clinical outcomes would be granted; however, 
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Table 1: Demographics of the sample with at-risk mental states (ARMS) and controls.
ARMS: At-risk mental state. The two groups are well matched for the main demographic potential confounders. 
SD: standard deviation.
Figure 1: P300 and N100 amplitude and latency comparisons between at risk cases and controls
Bar chart providing P300 and N100 amplitude / latency (means ± 1 S.D) by electrode and group. 
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P300 amplitude: Coef.= -3.4 microvolt; 95%CI: -5.7 to -1.1;  p<0.01. 
P300 latency:  Coef.= 1.9 microvolt; 95%CI: -15.8 to -19.6;  p=0.83.
N100 amplitude:  Coef.= -0.1 microvolt; 95%CI: -1.3 to 1.0;  p=0.83.
N100 latency:  Coef.= -2.1 microvolt; 95%CI: -7.5 to 3.4;  p=0.46.
Figure 2: Group average P300 and N100 waves for 35 cases with at risk mental states and for 57 
controls
Group averages of P300 and N100 at sites FZ, CZ and PZ. No group differences observed in P300 latency or in the 


















Χ2 (1)= 1.674; P=0.43
Years ± SD 24.57±4.6 24.53±4.5
Age




19.37±3.2 20.60±3.7 T-test; P=0.10
Regular drug use % 31.4% 1.8% X (1); P < 0.001
Number of cigarettes/day ±sd 6.09±7.2 1.55±4.1 T-test; P<0.01
P300 performance  
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